Cargando…
Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
Ovarian carcinoma is one of the most common causes for cancer death in women; lack of early diagnosis and acquired resistance to platinum-based chemotherapy account for its poor prognosis and high mortality rate. As with other cancer types, ovarian cancer is characterized by dysregulated signaling p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094073/ https://www.ncbi.nlm.nih.gov/pubmed/35582305 http://dx.doi.org/10.20517/cdr.2021.20 |
_version_ | 1784705465330958336 |
---|---|
author | Romagnoli, Alice Maracci, Cristina D’Agostino, Mattia Teana, Anna La Marino, Daniele Di |
author_facet | Romagnoli, Alice Maracci, Cristina D’Agostino, Mattia Teana, Anna La Marino, Daniele Di |
author_sort | Romagnoli, Alice |
collection | PubMed |
description | Ovarian carcinoma is one of the most common causes for cancer death in women; lack of early diagnosis and acquired resistance to platinum-based chemotherapy account for its poor prognosis and high mortality rate. As with other cancer types, ovarian cancer is characterized by dysregulated signaling pathways and protein synthesis, which together contribute to rapid cellular growth and invasiveness. The mechanistic/mammalian target of rapamycin (mTOR) pathway represents the core of different signaling pathways regulating a number of essential steps in the cell, among which protein synthesis and the eukaryotic initiation factor 4E (eIF4E), the mRNA cap binding protein, is one of its downstream effectors. eIF4E is a limiting factor in translation initiation and its overexpression is a hallmark in many cancers. Because its action is regulated by a number of factors that compete for the same binding site, eIF4E is an ideal target for developing novel antineoplastic drugs. Several inhibitors targeting the mTOR signaling pathway have been designed thus far, however most of these molecules show poor stability and high toxicity in vivo. This minireview explores the possibility of targeting mTOR and eIF4E proteins, thus impacting on translation initiation in ovarian cancer, describing the most promising experimental strategies and specific inhibitors that have been shown to have an effect on other kinds of cancers. |
format | Online Article Text |
id | pubmed-9094073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | OAE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90940732022-05-16 Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy Romagnoli, Alice Maracci, Cristina D’Agostino, Mattia Teana, Anna La Marino, Daniele Di Cancer Drug Resist Review Ovarian carcinoma is one of the most common causes for cancer death in women; lack of early diagnosis and acquired resistance to platinum-based chemotherapy account for its poor prognosis and high mortality rate. As with other cancer types, ovarian cancer is characterized by dysregulated signaling pathways and protein synthesis, which together contribute to rapid cellular growth and invasiveness. The mechanistic/mammalian target of rapamycin (mTOR) pathway represents the core of different signaling pathways regulating a number of essential steps in the cell, among which protein synthesis and the eukaryotic initiation factor 4E (eIF4E), the mRNA cap binding protein, is one of its downstream effectors. eIF4E is a limiting factor in translation initiation and its overexpression is a hallmark in many cancers. Because its action is regulated by a number of factors that compete for the same binding site, eIF4E is an ideal target for developing novel antineoplastic drugs. Several inhibitors targeting the mTOR signaling pathway have been designed thus far, however most of these molecules show poor stability and high toxicity in vivo. This minireview explores the possibility of targeting mTOR and eIF4E proteins, thus impacting on translation initiation in ovarian cancer, describing the most promising experimental strategies and specific inhibitors that have been shown to have an effect on other kinds of cancers. OAE Publishing Inc. 2021-05-11 /pmc/articles/PMC9094073/ /pubmed/35582305 http://dx.doi.org/10.20517/cdr.2021.20 Text en © The Author(s) 2021. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Romagnoli, Alice Maracci, Cristina D’Agostino, Mattia Teana, Anna La Marino, Daniele Di Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy |
title | Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy |
title_full | Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy |
title_fullStr | Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy |
title_full_unstemmed | Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy |
title_short | Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy |
title_sort | targeting mtor and eif4e: a feasible scenario in ovarian cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094073/ https://www.ncbi.nlm.nih.gov/pubmed/35582305 http://dx.doi.org/10.20517/cdr.2021.20 |
work_keys_str_mv | AT romagnolialice targetingmtorandeif4eafeasiblescenarioinovariancancertherapy AT maraccicristina targetingmtorandeif4eafeasiblescenarioinovariancancertherapy AT dagostinomattia targetingmtorandeif4eafeasiblescenarioinovariancancertherapy AT teanaannala targetingmtorandeif4eafeasiblescenarioinovariancancertherapy AT marinodanieledi targetingmtorandeif4eafeasiblescenarioinovariancancertherapy |